-
公开(公告)号：US20140357656A1
公开(公告)日：2014-12-04
申请号：US14371075
申请日：2013-01-10
Applicant: Virginia Commonwealth University
Inventor： Yan Zhang , Kurt F. Hauser , Dana E. Selley
IPC: C07D489/08 , A61K31/485
CPC classification number: A61K47/481 , A61K31/485 , A61K47/55 , C07D489/08 , A61K2300/00
Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.
Abstract translation: 含有通过间隔基连接的两个药效团的二价配体，其中一个与μ-阿片受体（MOR）相互作用，另一个与辅助受体CC趋化因子受体5（CCR5）相互作用）用于治疗神经系统 诸如与艾滋病相关的疾病。
-
公开(公告)号：US09107954B2
公开(公告)日：2015-08-18
申请号：US14568859
申请日：2014-12-12
Applicant: Virginia Commonwealth University
Inventor： Yan Zhang , Kurt F. Hauser , Dana E. Selley
IPC: A61K31/485 , A61K47/48
CPC classification number: A61K47/481 , A61K31/485 , A61K47/55 , C07D489/08 , A61K2300/00
Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.
Abstract translation: 含有通过间隔基连接的两个药效团的二价配体，其中一个与μ-阿片受体（MOR）相互作用，另一个与辅助受体CC趋化因子受体5（CCR5）相互作用）用于治疗神经系统 诸如与艾滋病相关的疾病。
-
Patent Agency Ranking
公开(公告)号：US20150157730A1
公开(公告)日：2015-06-11
申请号：US14568859
申请日：2014-12-12
Applicant: Virginia Commonwealth University
Inventor： Yan Zhang , Kurt F. Hauser , Dana E. Selley
IPC: A61K47/48 , A61K31/485
CPC classification number: A61K47/481 , A61K31/485 , A61K47/55 , C07D489/08 , A61K2300/00
Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.
Abstract translation: 含有通过间隔基连接的两个药效团的二价配体，其中一个与μ-阿片受体（MOR）相互作用，另一个与辅助受体CC趋化因子受体5（CCR5）相互作用）用于治疗神经系统 诸如与艾滋病相关的疾病。
-
4.发明授权Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation 有权非肽，有效和选择性的阿片样物质受体拮抗剂及其在治疗阿片样物质成瘾和阿片样物质诱发便秘中的应用公开(公告)号：US08980908B2
公开(公告)日：2015-03-17
申请号：US14287254
申请日：2014-05-27
Applicant: Virginia Commonwealth University
Inventor： Yan Zhang , Dana E. Selley , William Dewey
IPC: A61K31/485 , C07D489/08 , G01N33/53
CPC classification number: C07D489/08 , G01N33/53 , G01N33/9486 , G01N2500/04
Abstract: Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction, as well as in the treatment of opioid induced constipation (OIC).
Abstract translation: 提供了μ阿片受体（MOR）的选择性非肽拮抗剂及其使用方法。 拮抗剂可以用于例如在竞争性结合测定中鉴定MOR激动剂，并且用于治疗与其中涉及MOR的成瘾有关的病症，例如， 海洛因，处方药和酒精成瘾，以及治疗阿片样物质诱发便秘（OIC）。
-
公开(公告)号：US08946254B2
公开(公告)日：2015-02-03
申请号：US14371075
申请日：2013-01-10
Applicant: Virginia Commonwealth University
Inventor： Yan Zhang , Kurt F. Hauser , Dana E. Selley
IPC: A61K31/485 , C07D489/08
CPC classification number: A61K47/481 , A61K31/485 , A61K47/55 , C07D489/08 , A61K2300/00
Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.
-
公开(公告)号：US10988481B2
公开(公告)日：2021-04-27
申请号：US16301765
申请日：2017-05-16
Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
Inventor： Yan Zhang , Dana E. Selley , William Dewey , Hamid Abkarali
IPC: A61P25/30 , C07D489/08 , A61P25/04
Abstract: Analogues of 6 α/β-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.
-
7.发明申请NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION 有权非肽，脂肪酸和选择性胡萝卜素受体拮抗剂及其在治疗阿片类药物和阿片样物质诱导剂中的应用公开(公告)号：US20140371255A1
公开(公告)日：2014-12-18
申请号：US14287254
申请日：2014-05-27
Applicant: Virginia Commonwealth University
Inventor： Yan Zhang , Dana E. Selley , William Dewey
IPC: C07D489/08 , G01N33/53
CPC classification number: C07D489/08 , G01N33/53 , G01N33/9486 , G01N2500/04
Abstract: Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction, as well as in the treatment of opioid induced constipation (OIC).
Abstract translation: 提供了μ阿片受体（MOR）的选择性非肽拮抗剂及其使用方法。 拮抗剂可以用于例如在竞争性结合测定中鉴定MOR激动剂，并且用于治疗与其中涉及MOR的成瘾有关的病症，例如， 海洛因，处方药和酒精成瘾，以及治疗阿片样物质诱发便秘（OIC）。
-
-
-
-
-
-
Search Results
7
records
(took 0.015 seconds)
